SAT0289 Impact of Psoriatic Arthritis (PSA) On Health Care Utilization (HCU) and Quality of Life (Qol)

Majed Khraishi, R. Aslanov, S. Khraishi,H. Zurel

Annals of the Rheumatic Diseases(2013)

引用 24|浏览3
暂无评分
摘要
Background Psoriatic arthritis (PSA) is a chronic condition that affects up to 1% of the general population and is associated with progressive joint damage, disability, and serious co-morbidities. Objectives To assess and compare utilization of healthcare services by patients with Early (EPsA) and Established (EstPsA) PsA To assess patients’ Quality of Life over 12 months Methods 151 patients with PsA were recruited from a rheumatology clinic and followed prospectively for a 12-month period. Fifty eight patients had EPsA and 93 had EstPsA (defined as Results At baseline, patients with EPsA utilized more health care services for arthritis and co-morbidities (e.g. CHD, Diabetes and Infections) than those with EstPsA: “ER” (0.12 vs. 0.09), “Doctor’s Office Visit” (0.91 vs. 0.72), “Specialist Visit” (0.86 vs.0.73), “Psychologist/Counsellor”(0.07vs.0.05) and “Physiotherapy/Rehabilitation” (0.26 vs. 0.19). Patients with EstPsA used more “Walk in Clinic” (0.12 vs. 0.09) and “Hospital Admittance” (0.05 vs. 0.02) services. DAS28 was strongly associated with HCU in both cohorts (EPsA: OR=1.3, p=0.049, 95%CI 1.0-1.7; EstPsA: OR=1.6, p=0.001, 95%CI 1.2-2.1). DAS28 and HAQ significantly correlated with QoL in both cohorts: EPsA: r=-0.28, p=0.002 and r=-0.41, p Conclusions PsA causes considerable disability and affects the QoL of patients even at early stages of the disease. Traditionally, it was felt that longer disease duration leads to greater health care utilization. However, our findings showed that patients with EPsA seem to utilize more health care services. Early initiation of treatment with DMARDs may reduce the burden of PsA on the health care system and improve patients’ well-being and quality of life. Disclosure of Interest M. Khraishi Grant/research support from: Dr. Khraishi received non restricted research grants from Hoffman-La Roche Canada, Amgen and Pfizer Canada, and Abbott Canada, R. Aslanov: None Declared, S. Khraishi: None Declared, H. Zurel: None Declared
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要